Evaluation of safety and Efficacy of Chymoral Forte in wound healing potential after orthopaedic surgery.
- Conditions
- Health Condition 1: null- Post orthopaedic surgery patient
- Registration Number
- CTRI/2011/07/001920
- Lead Sponsor
- Elder Pharmaceuticals Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 75
1.Patient of either sex between 18 to 60 years of age
2.Patient to undergo elective clean and uncontaminated surgery for open reduction of fracture
3.Patients willing to take the medications as directed
4.Willing to comply with the protocol requirements
5.Willing to give the written informed consent
1.Patients with known hypersensitivity to any of the study related drugs (i.e. trypsin-chymotrypsin , serratiopeptidase , Bromelain & Rutoside)
2.Patients undergoing emergency surgery & those with contaminated surgery
3.Patients with known hepatic or renal impairment
4.Patients not willing to give written informed consent
5.Uncontrolled diabetes mellitus or any other metabolic disorder.
6.Pediatric and Pregnant patients.
7.Treatment with any investigational drug in the preceding 4 weeks.
8.Any other condition that, in the opinion of the investigator, does not justify the inclusion of the subject in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method